Please login to the form below
37
Revenue 2017Invega Sustenna/Xeplion/Invega Trinza
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Invega Sustenna/Xeplion/Invega Trinza was produced by Roche.
J&J files three-monthly schizophrenia drug in Europe
J&J sells a once-monthly version of paliperidone as Invega Sustenna in the US and Xeplion in Europe, but the reduced dosing frequency could give the franchise a competitive advantage ... Xeplion/Invega Sustenna is already a big earner for J&J, with sales
FDA approves J&J’s schizophrenia drug Invega Trinza
The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Invega Sustenna, which is marketed as Xeplion in Europe, saw its 2014 sales grow by 27% to $1.6bn and J&J will be hopig Invega Trinza will
1
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Digital account director
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Sanofi to buy mRNA tech partner, Translate Bio, for $3.2bn
- Novartis to proceed with phase 3 trial for intrathecal OAV-101 in older SMA patients
- Ask the writers: Transitioning from academia to medical writing
- Amanda Pritchard becomes NHS England’s first female chief executive
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
- A market-adapted agile approach to launch excellence
- Communicating for change – creating effective medical communications
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
